We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Y-mAbs

News List

Y-mAbs announces FDA clearance of IND for its Lutetium-177 labelled omburtamab antibody pharmaceutical-business-review
October 21, 2020
Y-mAbs Therapeutics announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for 177Lu-omburtamab-DTPA for the treatment of medulloblastoma, which is the most common type of primary brain cancer..
Y-mAbs Secures Commercial Radiolabeling Capacity contractpharma
July 04, 2019
Enters agreement with SpectronRx to produce metastatic central nervous system neuroblastoma treatment, omburtamab.
MabVax Grants Sublicense to Y-mAbs for Neuroblastoma Vaccine americanpharmaceuticalreview
July 11, 2018
MabVax Therapeutics has granted to Y-mAbs Therapeutics an exclusive sublicense to a bi-valent ganglioside based vaccine intended to treat neuroblastoma, a rare pediatric cancer. A third of neuroblastoma patients are diagnosed as infants; and ninety percen